


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/673,735
Date Submitted: February 10, 2006				Filing Date	December 27, 2000
(use as many sheets as necessary)				First Named Inventor	Bernd DORKEN
				Group Art Unit	1643
				Examiner Name	Parithosh K. TUNGATUTHI
Sheet	1	of	2	Attorney Docket Number	028622-0102



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ³ (if known)			

U.S. PATENT APPLICATION DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Application Document		Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
PCT	A1	EDELSTEIN, M.L., et al., "Gene Therapy Clinical Trials Worldwide: 1989-2004 – An Overview", <i>J. Gene Med.</i> , vol. 6, pp. 597-605 (2004).			
	A2	REUSCH, U., et al., "Effect of Tetravalent Bispecific CD19 X CD3 Recombinant Antibody Construct and CD28 Costimulation of Lysis of Malignant B Cells from Patients with Chronic Lymphocytic Leukemia by Autologous T Cells", <i>Int. J. Cancer</i> , vol. 112, pp. 509-518 (2004).			
	A3	LOFFLER, A., et al. "A Recombinant Bispecific Single-Chain Antibody, CD19 X CD3, Induces Rapid and High Lymphoma-directed Cytotoxicity by Unstimulated T Lymphocytes", <i>Blood</i> , vol. 95, no. 6, pp. 2098-2103 (2000).			

Examiner Signature		Date Considered	3/23/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 10, 2006 (use as many sheets as necessary)				Complete if Known Application Number 09/673,735 Filing Date December 27, 2000 First Named Inventor Bernd DORKEN Group Art Unit 1643 Examiner Name Parithosh K. TUNGATHI Attorney Docket Number 028622-0102	
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.
PKT	A4	KIPRIYANOV, S.M., et al., "Bispecific Tandem Diabody for Tumor Therapy with Improved Antigen Binding and Pharmacokinetics", <i>J. Mol. Biol.</i> , vol. 293, pp. 41-56 (1999).
	A5	HOLLIGER, P., et al., "Diabodies: Small Bispecific Antibody Fragments", <i>Cancer Immunol. Immunother.</i> , vol. 45, pp. 128-130 (1997).
	A6	PEZZUTTO, A., et al., "CD19 Monoclonal Antibody HD37 Inhibits Anti-Immunoglobulin-induced B Cell Activation and Proliferation", <i>J. of Immunology</i> , vol. 138, no. 9, pp. 2793-2799 (1997).
	A7	CSOKA, M., et al., "Activation of T Cell Cytotoxicity Against Autologous Common Acute Lymphoblastic Leukemia (cALL) Blasts by CD3 X CD19 Bispecific Antibody", <i>Leukemia</i> , vol. 10, pp. 1765-1772 (1996).
	A8	DAVIS, B.M., et al., "Current Progress in the Gene Therapy of Cancer", <i>Current Opinion in Oncology</i> , vol. 8, pp. 499-508 (1996).
	A9	KIPRIYANOV, S.M., et al. "Rapid Detection of Recombinant Antibody Fragments Directed Against Cell-surface Antigens by Flow Cytometry", <i>J. of Immunological Methods</i> , vol. 196, pp. 51-62 (1996).
	A10	GRUBER, M., et al., "Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in <i>Escherichia coli</i> ", <i>J. of Immunology</i> , vol. 152, pp. 5368-5374 (1994).
	A11	HAYDEN, M.S., et al., "Single-chain Mono- and Bispecific Antibody Derivatives with Novel Biological Properties and Antitumour Activity from a COS Cell Transient Expression System", <i>Therapeutic Immunology</i> , vol. 1, pp. 3-15 (1994).
	A12	WEINER, G.J., et al., "The Role of T Cell Activation in Anti-CD3 X Antitumor Bispecific Antibody Therapy", <i>J. of Immunology</i> , vol. 152, pp. 2385-2392 (1994).
	A13	KOSTELNY, S.A., "Formation of a Bispecific Antibody by the Use of Leucine Zippers", <i>J. of Immunology</i> , vol. 148, no. 5, pp. 1547-1553 (1992).
	A14	TRAUNECKER, A., et al. "JANUSIN: New Molecular Design for Bispecific Reagents", <i>Int. J. Cancer</i> , Suppl. 7, pp. 51-52 (1992).

Examiner Signature		Date Considered	3/23/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.